Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Largest Shareholders Are Private Companies Who Were Rewarded as Market Cap Surged CN¥478m Last Week
Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Largest Shareholders Are Private Companies Who Were Rewarded as Market Cap Surged CN¥478m Last Week
Key Insights
主要见解
- Youcare Pharmaceutical Group's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
- 52% of the business is held by the top 5 shareholders
- Institutions own 21% of Youcare Pharmaceutical Group
- 悦康药业集团的私人公司所有权表明,重要的决策受到来自更大公众的股东影响。
- 前五大股东持有该公司52%的股份。
- 机构持有悦康药业集团21%的股份。
To get a sense of who is truly in control of Youcare Pharmaceutical Group Co., Ltd. (SHSE:688658), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are private companies with 43% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
为了了解真正控制悦康药业集团股份有限公司的人,重要的是了解企业的所有权结构。持有最多的是私人公司的43%所有权。换句话说,这个集团有可能从他们对该公司的投资中获得最多(或失去最多)利益。
Clearly, private companies benefitted the most after the company's market cap rose by CN¥478m last week.
显然,去周公司的市值上升了47800万人民币后,私人公司受益最大。
Let's delve deeper into each type of owner of Youcare Pharmaceutical Group, beginning with the chart below.
让我们深入研究悦康药业集团的每种所有者,首先从下面的图表开始。
What Does The Institutional Ownership Tell Us About Youcare Pharmaceutical Group?
机构持股可以为我们提供关于悦康药业集团的有用信息。我们可以看到悦康药业集团确实有机构投资者;他们持有公司的大部分股票。这表明公司在投资界具有一定的信誉度。但是,最好谨慎地依赖机构投资者所做的所谓验证。他们有时也会犯错。如果多个机构同时改变对股票的看法,您可能会看到股价快速下跌。因此,看一下悦康药业集团下面的收益历史很有必要,当然,未来才真正重要。
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。
We can see that Youcare Pharmaceutical Group does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Youcare Pharmaceutical Group's earnings history below. Of course, the future is what really matters.
SHSE:688658 2024年7月20日收入与营业收入增长 我们可以看到,悦康药业集团确实有机构投资者;他们持有公司的大部分股票。这表明公司在投资界具有一定的信誉度。但是,最好谨慎地依赖机构投资者所做的所谓验证。他们有时也会犯错。如果多个机构同时改变对股票的看法,您可能会看到股价快速下跌。因此,看一下悦康药业集团下面的收益历史很有必要,当然,未来才真正重要。
Hedge funds don't have many shares in Youcare Pharmaceutical Group. Fuyang Jingyue Yongshun Information Consulting Co., Ltd. is currently the largest shareholder, with 40% of shares outstanding. Heze Sanrong Equity Investment Partnership Enterprise (Limited Partnership) is the second largest shareholder owning 3.2% of common stock, and Khorgos Jinran Equity Investment Management Partnership Enterprise (Limited Partnership) holds about 2.9% of the company stock. Additionally, the company's CEO Fei Yu directly holds 2.4% of the total shares outstanding.
悦康药业集团内部股权分布 我们可以报告,内部人员确实持有悦康药业集团股票..内部人员持有意义重大的持股,价值为2,0700万人民币。大多数人都会认为这是一个真正的好兆头。看到内部人员有这样的投资是好事。您可以在此处查看,看看这些内部人员是否最近一直在买入。
To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.
为了使我们的研究更有趣,我们发现前5位股东控制了该公司超过一半的股份,这意味着该组人对公司的决策具有相当大的影响力。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is some analyst coverage of the stock, but it could still become more well known, with time.
上海阿拉丁生物化学技术股份有限公司的内部人员拥有重要比例,内部人员在这家总价值27亿人民币的公司中持有12亿人民币的股份。这可能表明创始人仍然拥有很多股份。您可以单击此处查看他们是否进行了买卖。
Insider Ownership Of Youcare Pharmaceutical Group
私人公司拥有悦康药业集团股票的43%。仅仅从这一个事实很难得出任何结论,因此值得看看谁拥有这些私人公司的股份。有时内部人员或其他相关方通过一个独立的私人公司持有公共公司的股份。
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
虽然“内部人士”的明确定义具有主观性,但几乎所有人都认为董事会成员是内部人士。公司管理业务,但首席执行官即使是董事会成员,也要向董事会负责。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部所有权是积极的,因为它可以表示董事会与其他股东的利益相一致。但是,在某些场合下,这个团体的权力过于集中。
We can report that insiders do own shares in Youcare Pharmaceutical Group Co., Ltd.. The insiders have a meaningful stake worth CN¥207m. Most would see this as a real positive. It is good to see this level of investment by insiders. You can check here to see if those insiders have been buying recently.
尽管考虑拥有公司的不同群体很有价值,但还有更重要的因素。请注意,我们的投资分析显示,悦康药业集团显示了3个警告标志,其中1个是重要的...
General Public Ownership
一般大众所有权
The general public-- including retail investors -- own 33% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
查看一个公司是否值得通过考虑其股权组合来得知。但要想获得更全面的了解,我们必须考虑其他信息。请注意,在我们的投资分析中,汇顶科技展示了1个警告信号,你需要了解一下……
Private Company Ownership
私有公司的所有权
It seems that Private Companies own 43%, of the Youcare Pharmaceutical Group stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
请使用您的moomoo账号登录查看。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Youcare Pharmaceutical Group is showing 3 warning signs in our investment analysis , and 1 of those is significant...
请使用您的moomoo账号登录查看。
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
如果您想发现分析师对未来增长的预测,请不要错过这份有关分析师预测的免费报告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。